Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients

[1]  K. Danø,et al.  Plasminogen activator released as inactive proenzyme from murine cells transformed by sarcoma virus. , 2005, European Journal of Biochemistry.

[2]  N. Brünner,et al.  Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  A. Thor,et al.  Immunohistochemical localization of the plasminogen activator inhibitor‐1 in breast cancer , 1995, International journal of cancer.

[4]  N. Brünner,et al.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. , 1994, Cancer research.

[5]  J. Foekens,et al.  Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  K. Ulm,et al.  Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1. , 1994, Cancer research.

[7]  B. Ljung,et al.  The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. , 1994, Cancer research.

[8]  K. Danø,et al.  Enzyme-linked immunosorbent assay of urokinase-type plasminogen activator (uPA) in cytosolic extracts of human breast cancer tissue , 1993, Breast Cancer Research and Treatment.

[9]  N. Brünner,et al.  High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. , 1993, Cancer research.

[10]  N. Brünner,et al.  Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. , 1993, Cancer research.

[11]  J. Foekens,et al.  Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. , 1992, Cancer research.

[12]  S. Moestrup,et al.  Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. , 1992, The Journal of biological chemistry.

[13]  E. Appella,et al.  Internalization of the urokinase-plasminogen activator inhibitor type-1 complex is mediated by the urokinase receptor. , 1992, The Journal of biological chemistry.

[14]  P. Quax,et al.  Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. , 1991, Cell regulation.

[15]  D. Boyd,et al.  Role of the urokinase receptor in facilitating extracellular matrix invasion by cultured colon cancer. , 1991, Cancer research.

[16]  K. Danø,et al.  Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. , 1991, The Journal of biological chemistry.

[17]  K. Danø,et al.  Plasminogen Activation by Receptor-Bound Urokinase , 1991, Seminars in thrombosis and hemostasis.

[18]  F. Jänicke,et al.  Clinical Relevance of the Urokinase-Type and Tissue-Type Plasminogen Activators and of Their Type 1 Inhibitor in Breast Cancer , 1991, Seminars in thrombosis and hemostasis.

[19]  M. Duffy,et al.  Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. , 1990, Cancer research.

[20]  R. Medcalf,et al.  Plasminogen-activator inhibitor type 1 is a potent natural inhibitor of extracellular matrix degradation by fibrosarcoma and colon carcinoma cells. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[21]  L. Orci,et al.  The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes , 1990, The Journal of cell biology.

[22]  E. Appella,et al.  The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. , 1990, The Journal of biological chemistry.

[23]  K. Ulm,et al.  Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer , 1990 .

[24]  M. Cubellis,et al.  Receptor‐mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI‐1. , 1990, The EMBO journal.

[25]  E. Appella,et al.  Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. , 1990, The EMBO journal.

[26]  S. Stacey,et al.  Plasminogen activator inhibitors: hormonally regulated serpins , 1990, Molecular and Cellular Endocrinology.

[27]  R. Miskin,et al.  Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells , 1989, Molecular and cellular biology.

[28]  G M Clark,et al.  Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. , 1989, The New England journal of medicine.

[29]  L. Ossowski,et al.  In vivo invasion of modified chorioallantoic membrane by tumor cells: the role of cell surface-bound urokinase , 1988, The Journal of cell biology.

[30]  L. Lund,et al.  One-chain urokinase-type plasminogen activator from human sarcoma cells is a proenzyme with little or no intrinsic activity. , 1988, The Journal of biological chemistry.

[31]  M. Duffy,et al.  Urokinase‐plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report , 1988, Cancer.

[32]  G. Cassani,et al.  Binding of single-chain prourokinase to the urokinase receptor of human U937 cells. , 1986, The Journal of biological chemistry.

[33]  D. Rifkin,et al.  Tumor invasion through the human amniotic membrane: Requirement for a proteinase cascade , 1986, Cell.

[34]  L. Ossowski,et al.  Antibodies to plasminogen activator inhibit human tumor metastasis , 1983, Cell.

[35]  J. Zeuthen,et al.  Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. , 1982, Biochemistry.

[36]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[37]  B. Nielsen,et al.  Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[38]  N. Brünner,et al.  Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. , 1994, Cancer research.

[39]  J. Foekens,et al.  The prognostic value of plasminogen-activator inhibitor-1 (PAI-1) and the metastasis-associated proteases urokinase (uPA) and cathepsin-D in primary breast cancer: A multivariate analysis in 657 patients , 1993 .

[40]  C. Mountford,et al.  Evaluation of an in vitro invasion assay for use on solid tissue samples and cultured cells. , 1992, Invasion and Metastasis.

[41]  L. Ossowski,et al.  Inhibition of urokinase-type plasminogen activator by antibodies: the effect on dissemination of a human tumor in the nude mouse. , 1991, Cancer research.

[42]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[43]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[44]  H. Kobayashi,et al.  Modulation of Urokinase-type Plasminogen Activator and Ovarian Cancer Cell Invasion by in Vitro Inhibition of Updated Version Citing Articles E-mail Alerts Inhibition of in Vitro Ovarian Cancer Cell Invasion by Modulation of Urokinase- Type Plasminogen Activator and Cathepsin B , 2022 .